TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Industry News Articles > Brexit transition period drawing to a close

Brexit transition period drawing to a close

While the UK left the EU on the 31 January 2020, it did so under the auspices of the Withdrawal Agreement which covered issues such as citizens’ rights, the Irish border and the financial settlement the UK will pay the EU. The current 11-month transition period up until December 31 2020was intended to work out the ‘future relationship’ on trade, security, immigration, fishing, aviation etc. In this transition period, the UK continues to follow EU rules and trade continues between the UK and EU as before. The deadline for extending the transition period has been passed and if there is no trade deal by 31 Dec 2020, the UK will no longer be part of the EU’s two main trading arrangements: the single market and the customs union.

This will mean that the UK will no longer share the same rules on product and service standards. Goods, services and money will no longer be moved freely between the UK and the EU. It will also remove the agreement between the EU and the UK not to charge tariffs on each other’s goods. The corollary here is that without a trade deal:

  • Tariffs may be applied by the EU or UK on each other’s goods
  • Border checks may be applied on each other’s freight
  • Market Access on services such as banking, financial services etc. may be limited
  • World Trade Organisation (WTO) trading rules would apply

Countries who operate under WTO rules have a list of tariffs (taxes on imports of goods) and quotas (limits on the number of goods) that they apply to other countries. Currently, the average EU tariff on third countries is relatively low, averaging as low as 2.8% for non-agricultural and up to 35% for dairy products.  In practice, developed countries keep medicines tariff free under the WTO Pharmaceutical Tariff Elimination Agreement, therefore the application of tariffs would be more relevant to API and excipients which are currently charged at approximately 4-6% across the EU.

The UK has already released details of the tariffs it will charge from January 2021 to countries with which it does not have a trade deal (which at the moment will include the EU). UK tariffs will be charged on most types of imported vehicles and on most agricultural products to protect these vulnerable sectors of the UK economy. Interestingly, the UK government removed many low % tariffs that it has been charging as part of the EU. The UK government has proposed 0% tariffs on finished dose pharmaceutical forms and 6% tariffs on APIs and excipients under the new UK Global Tariff list.

Perhaps more important than a trade deal are the ‘non-tariff barriers’ which include things such as product standards, safety regulations and checks on food and animals. The rules governing these are more complicated and even more critical than any of the tariffs that may be imposed. In this area of the negotiations, the UK and the EU will need to find ways to work with (or without!) each other’s regulations. In the absence of a trade deal, it is difficult to see how this would happen in the near future. This is why the Pharmaceutical and MedTech industries in both the UK and the EU have been working diligently to prepare for the worst case ‘no-deal’ scenario and the potential divergence of standards and regulations in this highly regulated industry. Such a possible, and now probable, divergence of standards and regulations across the healthcare sector contains all the complications that have been widely publicised by PharmaLex and others.

There are still many organisations who have chosen to adopt a ‘wait-and-see’ approach to Brexit. The pharmaceutical industry was recently informed by the HPRA in Ireland that a number of pharmaceutical products are still ‘non-compliant’ with regard to: the relocation of Marketing Authorisation Holders, the relocation of sites of batch release, and the testing of medicinal products in the EU. It would appear that the waiting is nearly over and despite recent brinkmanship we are now moving into the final phase where the pharmaceutical regulatory paths of the UK and EU may become slightly clearer.

If you are unsure of your responsibilities with regard to Brexit or you require assurance that your organisation is suitably prepared for the changes that will occur on December 31 2020, please do not hesitate to contact us on +353 1 846 4742 or contact@pharmalex.com

Related posts
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Virtual Audits: To be, or not to be, that is the question
Virtual Audits: To be, or not to be, that is the question
26th January 2022
Quality Risk Management ICH Q9 – Revision published for public comments
Quality Risk Management ICH Q9 – Revision published for public comments
5th January 2022
Search
Upcoming Events

September 28 - May 29th, 2022

NLS DAYS 2022

Visit us at booth X51

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
17 May

At PharmaLex, one of our core values is expanding our global community. In March, we welcomed Japan, East Asia, and Southeast Asia into our global pharmaceutical #productdevelopment as a result of a merger agreement with Ascent Development Services.
https://lnkd.in/eGFf_AKv

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • They are available when we need to talk to them despite any time zone differentials

    Japan based medium sized company
    Manager
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for